Apellis Was Informed Of Negative Trend Vote Pegcetacoplan European Application, Apellis Expects The CHMP To Adopt Negative Opinion At Its Next Meeting In January
Portfolio Pulse from Benzinga Newsdesk
Apellis Pharmaceuticals was informed of a negative trend vote regarding its European application for Pegcetacoplan. The company anticipates a negative opinion from the CHMP at its January meeting and plans to appeal and seek re-examination if this occurs.
December 14, 2023 | 12:14 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Apellis Pharmaceuticals is likely to face a negative opinion from the CHMP on its drug Pegcetacoplan, which could impact the company's European market prospects. They plan to appeal the decision.
The negative trend vote from the CHMP is a significant regulatory hurdle for Apellis, potentially delaying or preventing market access in Europe for Pegcetacoplan. The intention to appeal shows the company's commitment to the drug, but the short-term impact is likely negative due to the uncertainty and potential delay in approval.
CONFIDENCE 80
IMPORTANCE 90
RELEVANCE 100